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Abstract
Background: CREB3L1 (cAMP-responsive element-binding protein 3-like protein 1), a member of the unfolded
protein response, has recently been identified as a metastasis suppressor in both breast and bladder cancer.
Methods: Quantitative real time PCR (qPCR) and immunoblotting were used to determine the impact of histone
deacetylation and DNA methylation inhibitors on CREB3L1 expression in breast cancer cell lines. Breast cancer cell
lines and tumor samples were analyzed similarly, and CREB3L1 gene methylation was determined using sodium
bisulfite conversion and DNA sequencing. Immunohistochemistry was used to determine nuclear versus cytoplasmic
CREB3L1 protein. Large breast cancer database analyses were carried out to examine relationships between CREB3L1
gene methylation and mRNA expression in addition to CREB3L1 mRNA expression and prognosis.
Results: This study demonstrates that the low CREB3L1 expression previously seen in highly metastatic breast cancer
cell lines is caused in part by epigenetic silencing. Treatment of several highly metastatic breast cancer cell lines that
had low CREB3L1 expression with DNA methyltransferase and histone deacetylase inhibitors induced expression of
CREB3L1, both mRNA and protein. In human breast tumors, CREB3L1 mRNA expression was upregulated in low and
medium-grade tumors, most frequently of the luminal and HER2 amplified subtypes. In contrast, CREB3L1 expression
was repressed in high-grade tumors, and its loss was most frequently associated with triple negative breast cancers
(TNBCs). Importantly, bioinformatics analyses of tumor databases support these findings, with methylation of the
CREB3L1 gene associated with TNBCs, and strongly negatively correlated with CREB3L1 mRNA expression. Decreased
CREB3L1 mRNA expression was associated with increased tumor grade and reduced progression-free survival. An
immunohistochemistry analysis revealed that low-grade breast tumors frequently had nuclear CREB3L1 protein, in
contrast to the high-grade breast tumors in which CREB3L1 was cytoplasmic, suggesting that differential localization
may also regulate CREB3L1 effectiveness in metastasis suppression.
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Conclusions: Our data further strengthens the role for CREB3L1 as a metastasis suppressor in breast cancer and
demonstrates that epigenetic silencing is a major regulator of the loss of CREB3L1 expression. We also highlight that
CREB3L1 expression is frequently altered in many cancer types suggesting that it could have a broader role in cancer
progression and metastasis.
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Background
CREB3L1 is a member of the CREB/ATF family of
transcription factors and functions as a transducer of the
unfolded protein response (UPR) [1]. A large fraction of
proteins synthesized in the cell undergo folding and
post-translational modification in the endoplasmic
reticulum before being released to perform their desired
function. This process can be disrupted by endoplasmic
reticulum stress resulting from hypoxia, glucose or nu-
trient depletion, change in calcium homeostasis, or ex-
pression of mutant or misfolded proteins, and can lead
to the accumulation of unfolded proteins that if released
from the endoplasmic reticulum can have detrimental
effects. The accumulation of unfolded proteins in the
lumen of the endoplasmic reticulum initiates the UPR.
The UPR works to regain endoplasmic reticulum
homeostasis by reducing protein translocation into the
endoplasmic reticulum, increasing the protein-folding
capacity of this organelle, decreasing translation initi-
ation, and increasing protein degradation [2]. Prolonged
activation of the UPR leads to apoptosis [3].
There are three main transducers of the UPR, namely
activating transcription factor-6 (ATF6), inositol requir-
ing 1 (IRE1), and PRK-like endoplasmic reticulum kinase
(PERK). Under non-stress conditions they are held in
their inactive form by association with chaperone pro-
teins, such as GRP78, bound to their endoplasmic
reticulum luminal domain. As unfolded proteins accu-
mulate in the endoplasmic reticulum, GRP78 disassoci-
ates from ATF6, IRE1, and PERK, and binds to the
hydrophobic regions of unfolded proteins, which are
subsequently either refolded, or ubiquitinated and de-
graded [4]. Activated IRE1 cleaves the mRNA of X-box
binding protein 1 (XBP1). The spliced form of XBP1 is
translated into a potent transcriptional activator that
stimulates the transcription of UPR target genes. PERK
phosphorylates eIF2α, which in turn causes a global re-
duction in mRNA translation. Paradoxically, phosphory-
lated eIF2α also selectively promotes the translation of
specific mRNAs, such as ATF4 [5], which activates the
transcription of genes involved in amino acid metabol-
ism and apoptosis [6].
CREB3L1, also termed OASIS (old astrocyte
specifically-induced substance) in mice, is the most
recently identified member of the UPR containing
both a bZIP domain and a DNA binding domain [1].
CREB3L1 is located on chromosome 11, a chromo-
some that contains a number of loci that are fre-
quently altered in breast cancer [7–9]. It is an
endoplasmic reticulum transmembrane protein and
activated in a similar manner to ATF6, via Site-1-
protease (S1P) and S2P cleavage in the Golgi appar-
atus followed by translocation to the nucleus [10].
This mature activated form is a transcription factor,
acting on both endoplasmic reticulum stress respon-
sive elements (ESRE) and cyclic AMP responsive ele-
ments (CRE) to increase expression of target genes
such as GRP78 [11].
A number of studies have identified roles for the
members of the UPR in breast cancer development, pro-
gression and resistance to therapy. PERK expression has
been shown to be vital for the initiation and progression
of breast cancers. Inhibition of PERK expression in ani-
mal models results in an increase in reactive oxygen spe-
cies leading to increased DNA damage and a halting of
the cell cycle [12]. ATF4 activation was shown to confer
resistance to the chemotherapy agent taxol in hypoxic
tumors [13]. A similar finding demonstrated that in-
creased expression of GRP78 is associated with che-
moresistance in breast cancer [14, 15]. XBP1 expression
has been linked to resistance to anti-estrogen therapies,
including tamoxifen, which is especially problematic as
XBP1 is rapidly induced by estrogens [16–18]. Recently
XBP1 has been shown to be important in driving TNBC
oncogenesis through the formation of transcriptional
complexes with hypoxia inducing factor 1α (HIF1α) [19].
Although not specific to breast cancer, CREB3L1, like
the other members of the UPR, has also been shown to
perform important roles in cancer. Epigenetic downreg-
ulation of CREB3L1 mRNA expression by DNA methy-
lation is associated with increased tumor grade and
aggressive phenotype in bladder cancer [20]. Also,
CREB3L1 has been shown to be necessary for the che-
motherapeutic drug doxorubicin to block cell prolifera-
tion and may function as a biomarker in predicting
response to therapy [21, 22]. Doxorubicin increases cer-
amide production, which in turn stimulates regulated
intramembrane proteolysis of CREB3L1 to its mature ac-
tive form. CREB3L1 then activates expression of target
genes, including p21, a cell cycle inhibitor [21, 23]. In
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addition, CREB3L1 may also play a role in limiting the
spread of viral expression as CREB3L1 expression blocks
proliferation of virally infected Huh7 cells [24].
Our previous work showed that highly metastatic rat and
human breast cancer cell lines had reduced expression of
CREB3L1 compared to poorly metastatic breast cancer cell
lines [25]. We further showed that re-expression of
CREB3L1 reduced the in vitro metastatic cell properties,
including cell migration, invasion, survival under hypoxic
conditions and anchorage-independent growth. In a rat
model of breast cancer, CREB3L1-re-expressing cells
initially formed large tumors (>0.5 cm3), in which 70 % of
them regressed to a nearly undetectable size. None of these
rats had metastases as compared to a 90 % metastasis rate
for the rats with the corresponding CREB3L1-deficient
cells [25]. These results suggest that CREB3L1 plays a key
role in suppressing tumorigenesis and metastasis.
In this report, we characterize the expression of
CREB3L1 in a large panel of breast cancer and non-cancer
cell lines and determine whether epigenetic mechanisms
regulate CREB3L1 expression in breast cancer. In addition,
we characterize CREB3L1 mRNA expression, gene methy-
lation and protein localization in a large number of human
tumor samples. Finally, we expanded our analysis of tumor
samples from the Cancer Genome Atlas with associated




A panel containing 40 breast cancer cell lines (and 4
non-tumorigenic breast cell lines) was obtained from the
American Type Culture Collection (ATCC, Manassas,
Virginia, USA 30-4500 K). Cells were cultured according
to ATCC recommendations for fewer than 6 months
from the time of resuscitation. All cell lines were au-
thenticated by the supplier (http://www.ATCC.org).
To examine the impact of DNA methylation and/or
histone acetylation on CREB3L1 expression, the human
breast cancer cell lines BT20, HCC1806 and MDA-MB-
468 cells were treated with a DNA methyltransferase in-
hibitor, 5-aza-2′-deoxycytidine (DAC) (Sigma Aldrich,
Oakville, ON, Canada), and/or a histone deacetylase in-
hibitor, trichostatin A (TSA) (Sigma Aldrich, Oakville,
ON, Canada). Cells were grown to 60–70 % confluency
and treated with DAC (1 μM) for 96 hours (changing to
fresh DAC-containing media every 24 hours), with or
without TSA (1 μM), for the last 18 hours as previously
reported [26–28]. Cytotoxicity measurements were car-
ried out using a Cytotox Glo Cytotoxicity assay (Pro-
mega, Madison, WI, USA G9290) according to their
instructions, and no cytotoxicity was observed at 1 μM
TSA. Three independent experiments were performed
with triplicate samples, with one set used to prepare
DNA, one for RNA and the other lysed for western blot
analysis of CREB3L1 protein levels, as detailed below. In
some instances, cells were treated with the proteasomal
inhibitor, MG132 (Sigma Aldrich, Oakville, ON,
Canada), at a concentration of 3 μM for the last 18 hours
prior to lysis, to prevent the degradation of CREB3L1
protein and better enable visualization on western blots.
Breast tumor samples
Sections from 216 human primary breast tumors and
corresponding de-identified clinical data were obtained
from the Manitoba Breast Tumor Bank (Winnipeg, MB,
Canada). Four different tumor types were obtained in-
cluding: infiltrating ductile, infiltrating colloid, infiltrat-
ing lobular and infiltrating papillary. For the purposes of
assessing the possible correlation between low CREB3L1
expression and more advanced or aggressive tumor type,
we have ordered these tumor types from least to most
aggressive (colloid, lobular, ductile, papillary) based on
several sources [29–33]. Tumor samples were graded by
pathologists at the time of diagnosis based on mitotic
count, nuclear pleomorphisms and tubule formation,
from low (grade 4) to high (grade 9) according to the
Nottingham derivation of the Scarff Bloom Richardson
system, in which grades 4 to 5 are low, 6 to 7 are
medium, and 8 to 9 are high [34]. The estrogen and pro-
gesterone receptor status of the tumors was also pro-
vided by the Manitoba Breast Tumor Bank. No data
were available for the human epidermal growth factor
receptor 2 (HER2) status of these samples. Each section
consisted of 40–70 % invasive tissue, with the remainder
of the tissue being composed of stroma and fat. Sam-
ples were accessed and handled according to approved
ethics committee guidelines at both the University of
Saskatchewan and the Manitoba Tumor Bank (ethics
approval number 14-37).
Western blot analysis
CREB3L1 protein expression in breast cancer cell lines was
quantified by western blot analysis as previously described
[35]. Briefly, SDS-PAGE was performed using 50 μg total
protein, unless otherwise stated, as determined by Lowry
(Sigma Aldrich, Oakville, ON, Canada TP0300). Samples
were transferred to nitrocellulose and were probed with
CREB3L1 (11235-2-AP from Protein Tech, Rosemont, IL,
USA; rabbit, 1:500) or ß-actin (C-4 from Santa Cruz -
Biotechnology, Dallas, TX, USA; mouse, 1:500) primary
antibodies, followed by infrared 680 nm or 800 nm
dye-tagged secondary antibodies (LI-COR Biosciences,
Lincoln, NE, USA; 200 ng/ml). Blots were imaged with the
Odyssey Infrared Imaging System (LI-COR Biosciences,
Lincoln, NE, USA), quantified, normalized to a ß-actin
loading control, and reported relative to that in
MDA-kB2 cells.
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Methylation sequencing
DNA was extracted from breast tumor sections and cell
cultures using the QIAamp DNA Mini Kit (Qiagen, To-
ronto, ON, Canada). Sodium bisulfite treatment was per-
formed using the EpiTect Bisulfite kit (Qiagen, Toronto,
ON, Canada) to convert unmethylated cytosine residues
to uracil according to the supplier’s instructions. CpGe-
nome Human Methylated DNA Standard, (Cedarlane,
Burlington, ON, Canada) and Epitect Control unmethy-
lated DNA (Qiagen, Toronto, ON, Canada) were used as
positive and negative controls, respectively.
Primers were designed using Primer3 software [36] to
amplify (from bisulfite-treated DNA) two overlapping
fragments of CREB3L1 spanning base pair −492 to +290
relative to the transcription start site (Additional file 1:
Table S1). Our preliminary data indicated that DNA
methylation was concentrated within the beginning of
the coding region, thus, a set of primers that amplify a
fragment from −51 to +258 to target this methylation-
rich region was used. PCR was performed with 100 ng
bisulfite-treated DNA in a 50-μl reaction with the
TaKaRa EpiTaq HS kit (Cedarlane, Burlington, ON,
Canada) according to the supplier’s instructions. The
thermocycling protocol consisted of 45 cycles of 10 sec-
onds at 98 °C, 30 seconds at annealing temperature
(Additional file 1: Table S1), and 1 minute at 72 °C. QIA-
quick PCR Purification Kit (Qiagen, Toronto, ON,
Canada) was used to purify PCR products prior to se-
quencing. Sanger sequencing was performed by the
Plant Biotechnology Institute (Saskatoon, SK, Canada)
and results were visualized with MacVector version 12.5
software (MacVector, Inc., Apex, NC, USA). Only se-
quences containing efficient C to T conversions, indica-
tive of effective sodium bisulfite conversion at the non-
CpG sites (that would not be methylated) were used for
methylation analyses. Sequences were assessed for the
presence of methylated cytosine residues at CpG di-
nucleotide motifs by using a qualitative assessment at
each possible methylated position. Methylation was
scored as low, but present and given a value of 1, if the
C peak was above background noise even if some T was
also present. Methylation was scored as high and given a
value of 2, if the C peak was the tallest peak observed
at that position. Initially sequences were analyzed
from −429 to +259, relative to the translational start site, a
region that includes 60 CpG sites. As most methylations
were concentrated between −15 and +259, subsequent
analyses focused on these 24 CpG sites.
Quantitative real-time PCR
Total RNA was extracted from cell lines using the
RNeasy kit (Qiagen, Toronto, ON, Canada) and from
breast tumor sections using the PicoPure RNA Isolation
kit (Life Technologies). RNA was reverse-transcribed to
cDNA using Superscript II Reverse Transcriptase and
oligo-dT primers (Invitrogen) according to the supplier’s
instructions. CREB3L1 expression was measured by
quantitative real-time PCR performed using TaqMan
probes (assay ID Hs00999642_m1, Life Technologies,
Waltham, MA, USA) and TaqMan Gene Expression
Master Mix (Life Technologies, Waltham, MA, USA) ac-
cording to manufacturer’s protocols. The sequence of these
primers is proprietary, but it amplifies a 103-bp fragment at
the junction of exons 8 and 9 such that it will only detect
the full-length transcript. Relative expression was calculated
using expression of glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) (assay ID Hs99999905_m1,
Life Technologies, Waltham, MA, USA) as a reference
gene. Samples were analyzed in triplicate per reaction
using the StepOnePlus Real-Time PCR System (Applied
Biosystems, Waltham, MA, USA). Results are the mean of
two independent reactions and reported as the relative
change in expression compared to the MDA-kB2 cell line
(for the cell line analysis), or control normal breast tissue
sample (Manitoba Breast Tumor Bank, Winnipeg, MB,
Canada) for the tumor sample analysis. Where samples
were available, the HER2 status of the tumor samples was
determined by qPCR as above, but using HER2-specific
TaqMan probes (assay ID Hs1001580_m1, Life Technolo-
gies, Waltham, MA, USA), relative to a GAPDH reference
gene. HER2 status was reported as compared to the
MDA-kB2 cell line (HER2-positive, but not amplified) as
follows (negative <1, positive = 1–9, amplified >9).
Copy number variation
CREB3L1 gene copy number was assessed using a digital
droplet PCR assay [37]. The number of target fragments
in the original sample is calculated using a Poisson dis-
tribution and the copy number of the gene of interest is
calculated by normalizing it to a reference gene (AP3B1)
to adjust for global ploidy changes [38].
DNA extracted from human breast tumors was
digested with HaeIII (New England Biolabs, Whitby,
ON, Canada) prior to analysis, as per supplier’s instruc-
tions. To measure CREB3L1 gene copy number, custom-
designed CREB3L1 primers and FAM-labeled TaqMan
probe (forward 5′- GATCCAGCTTCCTGGACTTG-3′,
reverse 5′-GTAAGATGAAGGGTCTCCGTTC-3′, probe
5′-ACGAGTCGGACTTCCTCAACAATGC-3′; Bio-Rad,
Mississaugo, ON, Canada) were combined in a duplex
reaction with pre-validated AP3B1 primers and HEX-
labeled TaqMan probe (assay ID dHsaCP1000483,
Bio-Rad, Mississaugo, ON, Canada) and ddPCR Supermix
for Probes (Bio-Rad, Mississaugo, ON, Canada). Droplets
were generated using the QX100 Droplet Generator
(Bio-Rad, Mississaugo, ON, Canada) and thermocycled to
the completion of the following protocol: 10 minutes at
95 °C; 40 cycles of 30 seconds at 94 °C and 1 minute at
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60 °C; 10 minutes at 98 °C. Droplets were analyzed using
the QX100 Droplet Reader (Bio-Rad, Mississaugo, ON,
Canada) and copy numbers were computed with Quanta-
Soft software (Bio-Rad, Mississaugo, ON, Canada) after
normalization to AP3B1. Results are reported as the aver-
age copy number of CREB3L1 genes per cell.
Immunohistochemistry
Immunohistochemical staining of CREB3L1 protein was
performed on formalin-fixed paraffin-embedded human
breast tumor samples obtained from the Manitoba
Tumor Bank, according to the manufacturer’s instruc-
tions using Pierce Peroxidase Detection Kit (Thermo
Scientific, Burlington, ON, Canada). Briefly, sections
were de-paraffinized and heated in citrate buffer (pH =
6), followed by an overnight incubation at 4 °C with a
rabbit polyclonal anti-CREB3L1 antibody (1:100; Protein
Tech, Rosemont, IL, USA 11235-2-AP). Subsequently,
slides were incubated with a horseradish peroxidase goat
anti-rabbit secondary antibody (1:1000; Abcam, Toronto,
ON, Canada ab6721) for 2 hours at room temperature and
reacted with 3,3′-Diaminobenzidine (DAB) for 15 minutes.
Sections were counterstained with hematoxylin. CREB3L1
staining was evaluated by a pathologist using two criteria,
staining intensity (absent = 0, weak = 1, moderate = 2,
strong = 3, very strong = 4) and % cells staining positive
(0–5 % = 0, 6–49 % = 1, 50–69 % = 2, 70–89 % = 3,
90–100 % = 4). Scores were added together and described
as little or no CREB3L1 staining (combined score 0–1),
low (scores 2–3), medium (scores 4–5) and high (scores
6–8) CREB3L1 expression, analogous to the Allred system
[39]. In addition, the subcellular location of CREB3L1 was
evaluated as nuclear or cytoplasmic.
In silico analysis
Publically available RNA-Seq Version 2 containing
normalized gene expression datasets for 24 different
cancer types were downloaded from the online data-
base, The Cancer Genome Atlas (TCGA; http://tcga-
data.nci.nih.gov). These data contained expression
profile, clinical information, tumor stage, and immu-
nohistochemical (IHC) results for the determination
of breast cancer subtype for each breast tissue sample.
The RNA-seq by expectation-maximization (RSEM) algo-
rithm-normalized gene expression profile was down-
loaded from TCGA. Although the microarray-based
dataset is also available in this database, to exclude prob-
lems that could be caused by combining different
platforms, measurement types, and normalization pro-
cedures, we used only the RNAseqV2 dataset for all
our gene expression analyses. To identify different
subtypes of breast cancer, we used the IHC annota-
tions available within our downloaded TCGA dataset.
This approach was further verified by an additional
independent analysis, where the TNBC population was de-
fined as the group of samples with the lowest 10 % of estro-
gen receptor (ER), progesterone receptor (PR) and HER2
expression. Analysis of these populations confirmed that
the same patients matched the IHC category. Similarly, for
stage-specific classification, the annotation of each patient
from the downloaded TCGA dataset was used. The
subtype classifications or stage-specific classifications
were analyzed using python scripts with pylab and
the scipy stat built-in libraries to generate the graphs
showing relationships with methylation and expres-
sion. The non-parametric Mann–Whitney U test was
used to compare two groups. The methylation data were
also downloaded from TCGA (Human Methylation 450 K
data). Methylation probes were deconvolved for every
single region across the promoter, and the intronic and
exonic regions. Normalized values were downloaded onto
Gene-E to generate the heatmap. Methylation data of
either selected regions as identified in Li et al. [40] or as
pre-selected by cBioPortal were used to generate correl-
ation analyses between methylation and gene expression.
The relationship between CREB3L1 methylation and
expression (Fig. 6c) was analyzed using cBioPortal
(http://www.cbioportal.org/index.do) [41, 42]. The data-
set analyzed was the breast invasive carcinoma (TCGA
Provisional) containing 737 cases, and was accessed
on 12 February 2015. Kaplan–Meier survival analysis
was carried out using KM-plotter (http://kmplot.com/
analysis/) [43]. Gene expression data and relapse-free
survival information were downloaded from Gene
Expression Omnibus (GEO) (Affymetrix microarrays only),
European Genome-phenome Archive (EGA) and TCGA.
The database is handled by a PostgreSQL server, which
integrates gene expression and clinical data simultaneously.
To analyze the prognostic value of a particular gene, the
patient samples were split into two groups at the median
of the proposed biomarker. The two patient cohorts were
compared using a Kaplan–Meier survival plot, and
the hazard ratio with 95 % confidence intervals and
log-rank p value were calculated. The database was
accessed on 22 February 2015.
Statistical analyses
Spearman correlations were determined using free on-
line software [44]. Statistical analyses were performed
using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA)
software. Significance was set at p <0.05 and error re-
ported as plus or minus the standard deviation (SD). The
non-parametric Mann–Whitney U test was used to com-
pare two groups. The Kruskal–Wallis test was used to
compare four or more groups of sample data, using SPSS
Statistics 23. Provided that significant differences were
detected by the Kruskal–Wallis test, a post-hoc test was
performed using pairwise comparisons. Survival analysis
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was performed using the Kaplan–Meier estimator with
the non-parametric log-rank test to measure the equity
of strata.
Results
CREB3L1 mRNA levels are low in most TNBC cell lines and
inversely correlate with CREB3L1 gene methylation in
human breast cancer cell lines
We analyzed CREB3L1 mRNA expression in a large
panel of 40 breast cancer cell lines using quantitative
real-time PCR (qPCR; Fig. 1a). In parallel, we measured
CREB3L1 protein levels using a quantitative western blot
analysis (Additional file 2: Figure S1 and Fig. 1a).
CREB3L1 protein was low in four non-tumorigenic nor-
mal breast cell lines (184B5, MCF10A, MCF10F and
MCF12A), and also in TNBC cell lines, as compared to
luminal and HER2 amplified cell lines (Fig. 1b). A posi-
tive correlation between CREB3L1 protein and mRNA
expression was observed (Spearman coefficient 0.315;
p = 0.048) (Fig. 1c).
Fig. 1 CREB3L1 gene methylation in breast cancer cell lines, and its inverse correlation with CREB3L1 expression. a A panel of 40 breast cancer
cells were analyzed in parallel for CREB3L1 gene methylation (% methylation, blue bars), mRNA (quantitative PCR (qPCR), red bars) and protein
expression (quantitative western blot, green bars). Percent methylation (data from Additional file 5: Table S2; left axis labels) were plotted together
with the relative CREB3L1 mRNA and protein expression (right axis labels). b The fraction of cell lines with low CREB3L1 protein expression in each
breast cancer subtype. c Positive correlation of CREB3L1 protein expression and its mRNA levels in breast cancer cell lines. Spearman correlation
(r value) and significance p value. d The fraction of cell lines containing CREB3L1 DNA methylation in each breast cancer subtype. Statistical
differences were analyzed by post-hoc pairwise comparison: *p <0.05. e Negative correlation of CREB3L1 mRNA expression and its DNA methylation
status in breast cancer cell lines. Spearman correlation (r value) and significance p value. HER2 human epidermal growth factor receptor 2, TNBC triple
negative breast cancer
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We analyzed the methylation status of the CREB3L1
promoter region, as one possible mechanism that could
regulate CREB3L1 expression in breast cancer cells. A
large CpG island (672 nucleotides) was identified in the
promoter region of the CREB3L1 gene, using the
University of California, Santa Cruz (UCSC) genome
browser [45] (Additional file 3: Figure S2 and Additional
file 4: Figure S3a). This CpG island contains 51 CpG
sites and extends from −119 nucleotides upstream of the
translational start site to 554 nucleotides into the coding
region of the gene. In addition, there are 27 CpG sites
between the transcriptional start site at −451 and the
start of the CpG island (Additional file 3: Figure S2). We
decided to analyze a fairly large region using sodium
bisulphite-treated DNA and Sanger sequencing [46–48].
This provided semiquantitative methylation data and
importantly allowed us to assess a relatively large region
including 60 CpG sites between −429 and +259
(Additional file 4: Figure S3b, c). We noted a strong
preferential methylation at the 3′ end of this region at CpG
sites 238 and 259. Samples with more extensive
methylation had additional methylations extending towards
the 5′ end of this region (Additional file 5: Table S2).
We found that more than half the breast cancer cell
lines contained CREB3L1 methylated CpG sites; in par-
ticular, those of the TNBC subtype of breast cancer were
highly methylated (Fig. 1a and d). In addition, four non-
tumorigenic normal breast cell lines (184B5, MCF10A,
MCF10F and MCF12A) all had many methylated sites in
the region analyzed (Additional file 5: Table S2 and
Fig. 1d). There was an inverse correlation between
CREB3L1 DNA methylation within this region and
CREB3L1 mRNA expression (Fig. 1e; Spearman correl-
ation −0.381, p = 0.015). These results suggest that
methylation of the CpG sites in the CREB3L1 gene may
in some cases negatively regulate CREB3L1 mRNA ex-
pression, particularly in TNBC cell lines.
To investigate the role of epigenetic mechanisms in
the regulation of CREB3L1 expression, the impact of the
DNA methyltransferase inhibitor, 5-aza-2′-deoxycytidine
(DAC), and the histone deacetylase inhibitor, TSA, were
tested [49–51]. BT20, HCC1806 and MDA-MB-468 hu-
man breast cancer cells were treated with DAC and/or
TSA and CREB3L1 mRNA levels were analyzed by
qPCR, relative to a GAPDH-specific control (Fig. 2a).
TSA strongly induced CREB3L1 mRNA levels in BT20
cells, whereas both TSA and DAC induced CREB3L1
mRNA in HCC1806 and MDA-MB-468 cells. Methyla-
tion analysis of CREB3L1 DNA in these samples showed
little or no change in BT20 cells, a small reduction in
the HCC1806 cells, and a larger reduction in the MDA-
MB-468 cells in response to DAC treatment (Fig. 2b).
These results were consistent with the effects of DAC
(±TSA) on CREB3L1 mRNA levels, suggesting that in
BT20 cells, CREB3L1 is not regulated significantly by
DNA methylation, but strongly by histone acetylation. In
contrast, CREB3L1 mRNA expression in MDA-MB-468,
and to a lesser extent HCC1806 cells, are regulated by
both DNA methylation and histone acetylation.
Parallel samples were assessed for CREB3L1 protein
levels by CREB3L1 immunoblotting (Fig. 2c) and showed
only modest increases upon TSA and/or DAC treatment.
As CREB3L1 protein levels have been reported to be
downregulated via constitutive ubiquitination and protea-
somal degradation in mouse embryo fibroblasts and C6
glioma cells [52], the TSA and/or DAC treatments were
repeated including the proteasomal inhibitor, MG132. The
presence of MG132 increased CREB3L1 protein levels
more robustly (Fig. 2c). These results suggest that both
epigenetic and post-translational mechanisms can contrib-
ute to reduced CREB3L1 in human breast cancer cells.
Nuclear CREB3L1 protein is decreased in high-grade
breast tumors
We further extended these studies from human breast
cancer cell lines to human breast cancer tissues. Tumor
samples included the associated data for ER and PR
status, but the HER2 status was unknown. Tumor grade
was provided for each sample and was determined using
the Nottingham derivation of the Scarff Bloom Richardson
system, where grades 4 to 5 are low, 6 to 7 are medium,
and 8 to 9 are high [34]. An IHC analysis was carried out
to characterize CREB3L1 protein expression and subcellu-
lar localization in 97 human breast tumor sections (Fig. 3).
Of the 97 samples stained, 56 (58 %) showed little or
no CREB3L1 staining (Fig. 3a–b). The samples with
CREB3L1 protein staining were further divided into
low (n = 9; Fig. 3c–d), medium (n = 14; Fig. 3e–f ) and
high (n = 18; Fig. 3g–h) based on the intensity and
frequency of CREB3L1 protein expression.
As a stress-activated protein, CREB3L1 resides within
the cytoplasm as an endoplasmic reticulum transmem-
brane protein, which can be processed after trafficking
to the Golgi to release an active transcription factor that
translocates into the nucleus. As has been noted in blad-
der cancer tumors [20], the 41 breast tumor samples
that expressed CREB3L1 protein showed two main
CREB3L1 localization patterns. Approximately half
(n = 19) had predominantly nuclear CREB3L1 protein
localization (Fig. 3c–f ), whereas the other half (n = 22)
had intense, mainly cytoplasmic staining (Fig. 3g–h). Im-
portantly, the low-grade breast tumors more frequently
had nuclear CREB3L1 protein, in contrast to the high-
grade breast tumors in which CREB3L1 was cytoplasmic
(p = 0.003, Mann–Whitney U test) (Fig. 3j). These results
suggest that when CREB3L1 protein is expressed in breast
tumors, the high-grade tumors have lost the nuclear
localization of this transcription factor.
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To assess whether there was any relationship between
different tumor subtypes and either overall CREB3L1
protein expression and/or subcellular localization, we
needed to determine their HER2 status. Where suffi-
cient tumor samples were available, we determined
the HER2 status using qPCR as detailed in “Methods”.
This allowed us to group the tumor samples into
molecular subtypes defined as: luminal (ER+ and/or
PR+, ± HER2 but not amplified levels), HER2 (HER2
amplified), and TNBC (ER–, PR–, HER2–). In the
absence of Ki67 data the luminal subtype was not
further stratified into luminal A and luminal B. The
amount of some samples was too small to determine
the HER2 status, and these were grouped as unknown.
There were no TNBC samples in our human tumor
specimens, although several of the unknown samples
were negative for ER and PR, but unknown for HER2
status.
For each subtype there were similar numbers of
samples with and without CREB3L1 staining (Additional
file 6: Figure S4a). Although the sample size within each
group was small, there was a larger proportion of HER2
amplified tumor samples with cytoplasmic CREB3L1
protein, rather than nuclear CREB3L1 (Additional file 6:
Figure S4b). We also compared the distribution of breast
cancer subtypes by their nuclear and cytoplasmic
localization and levels of CREB3L1 protein expression
(Fig. 4a). Luminal breast cancers were more frequently
observed to have low-medium levels of CREB3L1,
effectively localized to the nucleus, or high levels of
CREB3L1 within the cytoplasm. In contrast, HER2
amplified breast cancers contained mainly high levels
of cytoplasmic CREB3L1 (Fig. 4a). In parallel, luminal
breast cancers with nuclear CREB3L1 were most fre-
quently of low-medium grade, whereas those with
cytoplasmic CREB3L1 were often high-grade tumors
(Fig. 4b). This was not observed for the HER2 amplified
breast tumors. These results suggest that in HER2
amplified breast cancers about half express CREB3L1,
and the CREB3L1 is primarily localized in the cytoplasm
where its transcriptional regulation would not be active.
Further, in luminal breast cancers, again about half
express CREB3L1, that in lower grade tumors is typically
nuclear, where it could regulate transcriptional targets,
and in higher grade tumors is typically cytoplasmic, where
it could not.
Fig. 2 Trichostatin A (TSA) and to a lesser extent, 5-aza-2′-deoxycytidine (DAC) treatment induces CREB3L1 mRNA expression. a BT20, HCC1806
and MDA-MB-468 cells were treated with DAC ± TSA. CREB3L1 mRNA levels were quantified (qPCR) relative to a glyceraldehyde-3-phosphate
dehydrogenase (GAPDH)-specific control. Mean ± SD from three independent experiments: *p <0.05; **p <0.01. b CREB3L1 DNA methylation
was determined for each sample as for Fig. 1a and plotted with values for the original untreated cell line for comparison. c Parallel samples
were treated as in a and cell lysates (50 μg) were immunoblotted for CREB3L1. Additional samples were also treated where indicated with
the proteasomal inhibitor MG132 to block CREB3L1 protein degradation. Lysates from MDA-MB-175 cells were included as a positive control
for a cell line expressing endogenous CREB3L1. The full-length precursor form (approximately 84 kDa) of CREB3L1 is indicated with arrows;
*background band. β-actin levels are shown as loading controls. DMSO dimethyl sulfoxide
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Analysis of CREB3L1 mRNA expression and methylation in
human breast tumor samples
We measured CREB3L1 mRNA expression levels by
qPCR in 213 tumor samples and found that low- and
medium-grade tumors had increased CREB3L1 mRNA
expression when compared to normal breast tissue sam-
ples (Fig. 5a). In contrast, high-grade breast tumors had
reduced CREB3L1 expression. The majority of grade 8
(51 %) and grade 9 (73 %) breast tumors lacked
CREB3L1 mRNA expression (Fig. 5b). Overall, CREB3L1
mRNA expression was negatively correlated with tumor
type (r = −0.325, p <0.00001) and tumor grade (r = −0.342,
p <0.00001) (Table 1). In addition, CREB3L1 mRNA
expression was positively correlated with age at diagnosis
(r = 0.294, p <0.00001), estrogen receptor expression
(r = 0.232, p <0.001) and weakly with progesterone re-
ceptor expression (r = 0.158, p <0.05). These results
suggest that loss of CREB3L1 is more frequently seen
in high-grade, more aggressive breast cancers that
lack ER and PR expression.
Our breast cancer cell line data suggested that
CREB3L1 expression can be regulated in part by DNA
methylation. Therefore, we also analyzed CREB3L1
methylation in a large group of breast tumor samples
using the same approach we described above for the
breast cancer cell lines. Again, this provided qualita-
tive methylation data for 60 CpG sites between −429
and +259 (Additional file 7: Table S3). These tumor
samples generally showed less CREB3L1 DNA methy-
lation than the cell lines had, and similar to the cell
line data most methylation was clustered within the
3′ end of the region analyzed. Therefore, midway
through our analysis we narrowed our focus to the 24
CpG sites between −15 and +259 for about half of
these samples (Additional file 7: Table S3). In all we
analyzed 201 tumor samples and found 35 contained
Fig. 3 Immunohistochemical analyses of CREB3L1 protein expression in human breast tissue sections. Images were taken using × 10 (a, c, e, g)
and × 40 (b, d, f, h, i) objective. Little or no (a, b), low (c, d), medium (e, f) and high (g, h) CREB3L1-expressing breast tumor samples. i A negative
control sample where the primary antibody was omitted. j Loss of CREB3L1 protein within nuclei was associated with high-grade breast cancers
(n = 19 for nuclear; n = 22 for cytoplasmic). Diamonds medians, boxes 25–75 % quartiles, vertical lines range, peak and minimum; **p <0.01
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CREB3L1 methylation. Tumor samples with fewer meth-
ylated sites showed site-specific methylation at the most
3′ end including sites 221, 238 and 259 (Additional file 7:
Table S3). These results suggest a hierarchy with the sites
at the 3′ end of this −15 to +259 nucleotide region being
methylated preferentially to those upstream.
We observed one tumor that showed CREB3L1 DNA
methylation and had relatively high CREB3L1 mRNA
levels, prompting us to examine CREB3L1 gene copy
number. According to the Catalogue of Somatic
Mutations in Cancer (COSMIC) database, CREB3L1 is
rarely mutated in cancers but shows reduced copy num-
ber in 18 % (140/782) of breast cancers. In our samples
there were only a few breast tumors with alterations in
CREB3L1 copy number; 9 % had increased copy number
(3–5 copies), 4 % had a decreased copy number of 1
and 86 % had a normal copy number of 2. The tumor
with CREB3L1 DNA methylation but high CREB3L1
mRNA levels had a normal gene copy number (data
not shown).
We observed that CREB3L1 DNA methylation was
found in some samples within all tumor grades (Fig. 5c).
The high methylation frequency observed for grade 4 (3/
12 = 25 %) and grade 9 (2/10 = 20 %) were likely signifi-
cantly influenced by the relatively small sample sizes for
these two groups. The sample sizes within the remaining
tumor grades (5–8) were larger, making these data more
robust. Overall, CREB3L1 methylation was weakly, posi-
tively correlated with tumor type (r = 0.150, p <0.05) and
tumor grade (r = 0.146, p <0.05) (Table 2). In addition,
CREB3L1 methylation was weakly, negatively corre-
lated with age of diagnosis (r = −0.166, p <0.05), ER
expression (r = −0.168, p <0.05) and PR expression
(r = −0.143, p <0.05). Our data also showed weak
negative correlation between CREB3L1 mRNA expression
and CREB3L1 methylation (r = −0.149, p <0.036) (Fig. 5d).
These results suggest that the majority of the breast tumor
samples with DNA methylation had reduced CREB3L1
mRNA expression, implicating methylation as a mechan-
ism of CREB3L1 gene silencing.
Larger datasets support a role for CREB3L1 DNA
methylation in the regulation of CREB3L1 expression
We then expanded our analysis of CREB3L1 mRNA ex-
pression and methylation to the large TCGA dataset.
CREB3L1 mRNA levels were increased in breast tumors,
particularly for early-stage tumors (Fig. 6a). Similar to
what we had observed for our smaller tumor dataset,
CREB3L1 mRNA expression was increased in luminal
and HER2 breast cancers but was low in TNBC (Fig. 6b).
Fig. 4 Low-medium (med)-grade tumors express low amounts of nuclear CREB3L1 whereas high-grade tumors have high cytoplasmic localization.
Breast tumor samples (97) were analyzed by immunohistochemical analysis (IHC) (shown on Fig. 3) and were classified according to IHC staining
(a) and tumor grade (b), subdivided by tumor subtype (luminal, human epidermal growth factor receptor 2 (HER2) amplified, unknown) and nu-
clear versus cytoplasmic localization
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CREB3L1 mRNA expression also inversely correlated
with CREB3L1 DNA methylation as noted above (Fig. 6c,
cBioPortal: r = −0.464, p <0.0001). TNBCs were found to
have both the lowest CREB3L1 mRNA levels and the
highest CREB3L1 DNA methylation (Fig. 6d, p <0.0001),
suggesting the low CREB3L1 often observed in TNBC
cells may in part be due to increased methylation.
The methylation analysis carried out for these samples
included assessing 26 50- nucleotide regions, each con-
taining one or more CpG sites within the CREB3L1 gene
(Additional file 8: Table S4). Five of these regions did
not contain any methylation, and one had methylation
but it was unchanged in normal and tumor breast sam-
ples. The remaining 20 methylation regions were differ-
entially methylated between normal breast and breast
tumor samples (Fig. 6e). We assigned each of these 20
regions a number from 1–20 for easy reference and
show the location of each region that was analyzed, rela-
tive to the overall gene structure for CREB3L1 (Fig. 6f )
and their precise CpG-containing sequences for those in
the promoter region (Additional file 3: Figure S2). We
determined the relative methylation for each region in
normal versus breast tumor samples to assess which re-
gions might be involved in regulating CREB3L1 expres-
sion changes (Additional file 9: Figure S5a, b). Many of
the tested regions did not change their methylation sta-
tus appreciably, including those in the 5′ UTR (numbers
14, 1, 4, 6, 5, 7, and 8), some within the 20 kb intron 1
(numbers 15, 17, and 18), those within a second CpG
island within intron 1 (numbers 10, 11, 13, and 12), or
within intron 3 (number 9). We focused on the
remaining five regions (numbers 2, 3, 16, 19, and 20).
We found that methylation of two regions (numbers 2
and 3), within the first CpG island, negatively correlated
Fig. 5 CREB3L1 expression is reduced in high-grade human breast tumor samples. a CREB3L1 expression (mRNA) was determined from
213 human breast tumor tissue samples (qPCR) and plotted as fold change relative to the mean value from four normal breast tissue
samples (defined as zero on the scale), for each tumor grade. Median ± one quartile (numbers of samples for each grade 4–9: 12, 53, 48,
26, 63, 11): *p <0.05, as compared to grades 4–7; **p <0.01, as compared to grades 4–7. b A large percentage of the high-grade (8 and 9) tumors
lacked CREB3L1 mRNA expression (51 % and 73 %, respectively). An average of 53 % of high-grade breast tumors (8 and 9) are CREB3L
1-deficient. c CREB3L1 gene methylation was determined for 201 human breast tumor tissue samples, and was plotted for each tumor according to
grade (numbers of samples for each grade 4–9: 12, 50, 49, 23, 57, 10). d Negative correlation of CREB3L1 mRNA expression and the level of CREB3L1
DNA methylation (within nucleotides −15 to 238, relative to the translational start site) in 198 breast cancer tumor samples. Spearman correlation
(r value) and significance p value
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with CREB3L1 mRNA expression (Additional file 9:
Figure S5c), and they were less methylated in breast
tumor samples (Additional file 9: Figure S5a). The
remaining three regions (numbers 16, 19, and 20) are all
located in a shore near the second CpG island (Fig. 6f ).
Methylation in each of these regions positively corre-
lated with CREB3L1 mRNA expression (Additional
file 9: Figure S5d) and all were significantly more
methylated in breast tumor samples compared to nor-
mal breast tissue (Additional file 9: Figure S5b). The
inverse relationship between methylation at regions
number 2 and 3, coupled with the direct relationship
between methylation at regions number 16, 19, and
20 raises the possibility that complex methylation-
dependent changes at several regions within the
CREB3L1 gene (Additional file 10: Figure S6) could
contribute to the regulation of CREB3L1 expression
(Fig. 6b). When subdivided into low and high methylation,
as compared to the median methylation of the normal
breast samples, all five regions showed a significant
difference in the relative CREB3L1 mRNA expression
for the two groups (Additional file 11: Figure S7). Re-
gion number 2 showed the largest significant differ-
ence in methylation between normal breast and breast
tumors, suggesting that changes in methylation in this
region may have the largest influence on CREB3L1
Table 1 Clinico-pathological parameters of 213 human breast
tumor specimens in relation to CREB3L1 mRNA expression
CREB3L1 mRNA expressionb
Numbera Low High P valuec Spearman r
Parameter:
Age at diagnosis
<68 years 109 45 64 0.000013 0.294
≥68 years 104 25 79
Tumor type
Infiltrating ductile 170 66 104 0.000001 −0.325
Infiltrating colloid 22 0 22
Infiltrating lobular 20 2 18
Infiltrating papillary 1 1 0
Tumor graded
Grade 4 12 1 11 <0.000001 −0.342
Grade 5 53 11 42
Grade 6 48 11 37
Grade 7 26 6 20
Grade 8 63 32 31
Grade 9 11 8 3
Estrogen receptor
Negative 20 14 6 0.00064 0.232
Positive 193 55 138
Progesterone receptor
Negative 66 29 37 0.021 0.158
Positive 147 40 107
Lymph node status
Negative 69 23 46 0.120 −0.120
Positive 101 38 63
Unknown 43 8 35
aOnly patients with primary breast cancer were included. bBased on quantitative
real-time PCR results. cSignificance of Spearman rank correlation. Significant
p values are marked in boldface. dGraded according to the Nottingham derivation
of the Scarff Bloom Richardson system
Table 2 Clinico-pathological parameters of 201 human breast
tumor specimens in relation to CREB3L1 gene methylation
CREB3L1 methylationb
Numbera Low High P valuec Spearman r
Parameter:
Age at diagnosis
<68 years 100 79 21 0.018 −0.166
≥68 years 101 89 12
Tumor type
Infiltrating ductile 149 127 22 0.034 0.150
Infiltrating colloid 21 21 0
Infiltrating lobular 29 18 11
Infiltrating papillary 1 1 0
Infiltrating tubular 1 1 0
Tumor graded
Grade 4 12 9 3 0.038 0.146
Grade 5 50 48 2
Grade 6 49 41 8
Grade 7 23 18 5
Grade 8 57 44 13
Grade 9 10 8 2
Estrogen receptor
Negative 14 11 3 0.017 −0.168
Positive 187 157 30
Progesterone receptor
Negative 54 42 12 0.042 −0.143
Positive 147 126 21
Lymph node status
Negative 65 52 13 0.532 −0.050
Positive 93 77 16
Unknown 43 39 4
aOnly patients with primary breast cancer were included. bBased on DNA
sequencing results with and without sodium bisulfite treatment. cSignificance
of Spearman rank correlation. Significant p values are marked in boldface.
dGraded according to the Nottingham derivation of the Scarff Bloom
Richardson system
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Fig. 6 (See legend on next page.)
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mRNA expression. Region number 2 contains two
CpG sites at nucleotides 259 and 238 (Additional file 3:
Figure S2), the most frequently methylated within the
breast tumor cell lines and breast tumor samples that we
analyzed within our datasets (Additional file 5: Tables S2
and Additional file 7: Table S3).
Poor prognosis for patients with low CREB3L1 mRNA
expression in luminal A breast cancer and TNBC
Kaplan–Meier survival analysis was performed using
KM-plotter [43] with gene expression data and relapse-
free survival information accessed from several sources
including GEO (Affymetrix microarrays only), EGA and
TCGA (Fig. 7). When all breast cancers were analyzed
as a group there was a shorter relapse-ree survival time
for patients whose tumors contained low levels of
CREB3L1 mRNA expression (hazard ratio (HR) = 1.27;
p <0.0001) (Fig. 7a). When breast cancers were subdi-
vided into different molecular classifications, CREB3L1
mRNA expression did not significantly influence the
relapse-free survival time for luminal B (ER+ and/or
PR+, HER+ or HER2– with high Ki67) (Fig. 7c) and
HER2 (Fig. 7d) breast cancer patients. In contrast,
both luminal A (ER+ and/or PR+, HER2–, low Ki67)
(Fig. 7b) and triple negative (Fig. 7e) breast cancer
patients with low CREB3L1 mRNA expression had
higher HRs (1.49 and 1.33, respectively) that were statisti-
cally significant (p <0.00001 and p <0.05, respectively).
These results strongly implicate the loss of CREB3L1
expression as an indicator of poor prognosis in breast
cancers that are HER2–, such as luminal A and triple
negative.
Using the TCGA database, we determined if CREB3L1
mRNA expression was differentially regulated between
normal tissues and the corresponding tumor tissues
(Fig. 8). Several tumor tissues had little or no change
in CREB3L1 mRNA expression as compared to nor-
mal tissue, including esophageal cancer, glioblastoma
multiforme, head and neck squamous cell carcinoma,
lung adenocarcinoma, sarcoma, papillary thyroid car-
cinoma, thymoma and uterine corpus endometrial
carcinoma. A second group of cancers had signifi-
cantly higher CREB3L1 mRNA expression than their
normal counterparts, including breast carcinoma (p =
6.5 × 10−31), prostate adenocarcinoma (p = 1.5 × 10−11),
chromophobe renal cell carcinoma (p = 1.9 × 10−9), chol-
angiocarcinoma (p = 5.5 × 10−4), stomach adenocarcinoma
(p = 0.0025), liver hepatocellular carcinoma (p = 0.0027)
and pancreatic ductal carcinoma (p = 0.019). Although
these cancer types (including breast cancer) typically
show an increase in CREB3L1 expression, patients
with tumors expressing low levels of CREB3L1 may
experience a poorer prognosis, as we found for
breast cancer (Fig. 7a). A third group of cancers had
significantly lower CREB3L1 mRNA expression than
the corresponding normal tissues, including: lung
squamous cell carcinoma (p = 1.7 × 10−19), clear cell
kidney carcinoma (p = 1.2 × 10−10), papillary kidney car-
cinoma (p = 1.2 × 10−10), bladder urothelial carcinoma
(p = 2.8 × 10−6), colon adenocarcinoma (p = 0.00010),
pheochromocytoma and paraganglioma (p = 0.0029),
rectal adenocarcinoma (p = 0.0057), cutaneous melan-
oma (p = 0.043) and cervical squamous cell carcinoma
(p = 0.046). Thus, the loss of CREB3L1 is a frequent
occurrence and could play an important role in tumor
progression and metastasis in many cancer types.
Discussion
Previous investigations by our laboratory have impli-
cated CREB3L1 as a metastatic suppressor gene in breast
cancer models in vitro and in vivo. Transfection of
CREB3L1 into cells that normally express low levels of
CREB3L1 reduced cell migration, invasion, anchorage-
independent growth and tolerance of hypoxia [25]. Con-
sistent with these effects, knockdown of endogenous
CREB3L1 in cells demonstrated that loss of CREB3L1
(See figure on previous page.)
Fig. 6 CREB3L1 mRNA expression and DNA methylation from human breast tumor samples in The Cancer Genome Atlas (TCGA) database.
a, b CREB3L1 mRNA expression varies for different tumor stages (a: n = normal (70 samples); numbers of samples for each stage I to X:
80, 287, 139, 5, 4) and subtypes (b: numbers of samples: 70, 263, 15, 76) of breast tumors. Statistical differences were analyzed using
post-hoc pairwise comparison: *p <0.05; ***p <0.001. c Using cBioPortal containing TCGA data from 737 breast cancer cases, there is an
inverse relationship between CREB3L1 mRNA expression and CREB3L1 gene methylation that is very significant (Spearman correlation, r = −0.464,
p <0.001). d Focusing on samples where the tumor subtype was known, the lowest CREB3L1 mRNA expression and also the highest CREB3L1 gene
methylation was found most often in triple negative breast cancer (TNBC) (p <0.0001). e Data within TCGA contained an analysis of 26 regions
(50 nucleotides each) within the CREB3L1 gene that had been analyzed for DNA methylation (Additional file 8: Table S4). Of these, 20 showed
methylation changes between normal (97 samples) and breast tumors (764 samples), as shown (heat map): red high methylation, white mean
methylation, blue low methylation. Methylation regions are numbered (bottom (1–20)) with the sequences listed in Additional file 8: Table S4, and
their approximate locations are shown (f). f Schematic of CREB3L1 gene organization. The 5′ and 3′ untranslated regions (black boxes),
exons (gray boxes with numbers above) and CpG islands (hatched boxes) are shown. The first CpG island is 672 nucleotides long between −119
and 554, relative to the translational start site, and contains 51 CpG sites. The second CpG island is 610 nucleotides long between 17154 and
17822 within intron 1 and contains 56 CpG sites. The approximate locations of 20 cg probes for methylation are indicated underneath and
numbered as in e
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expression significantly increased migration, invasion,
anchorage-independent growth, and tolerance of hypoxia.
Further support for a role for CREB3L1 as a metastatic
suppressor was provided by in vivo studies where rats
were injected with CREB3L1-null or CREB3L1-expressing
cells. The CREB3L1-null cells formed large primary
tumors (29/30 animals) with frequent lymph node metas-
tases (26/30 animals) [25]. Strikingly, the CREB3L1-
expressing cells failed to develop metastases (0/30 ani-
mals) and after initially forming large tumors (>0.5 cm3),
70 % of these tumors (21/30) regressed to a nearly un-
detectable size [25].
Here we have expanded upon our previous study to
include 40 human breast cancer cell lines and over 200
human breast cancer tumor samples and investigated
DNA methylation and its role in the regulation of
Fig. 7 Poorer prognosis for luminal A breast cancer and triple negative breast cancer (TNBC) patients is associated with low expression of CREB3L1.
Kaplan–Meier relapse-free survival probability for breast cancer patients with high (red) and low (black) CREB3L1 gene expression (divided at the
median). The online software, KM plotter, was used to access gene expression data and relapse-free survival information from Gene Expression
Omnibus (Affymetrix microarrays only), European Genome-phenome Archive and The Cancer Genome Atlas. The two patient cohorts were
compared and the hazard ratio (HR) with 95 % confidence intervals and log-rank p value were calculated for the low versus high CREB3L1 levels.
Relapse-free survival probability for breast cancer patients: all (a; n = 3554), luminal A (b; n = 1764), luminal B (c; n = 1002), human epidermal
growth factor receptor 2 (HER2) amplified (d; n = 208) and triple negative (e; n = 580) divided into low or high CREB3L1 mRNA expression groups
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CREB3L1 expression. We found that in luminal and
HER2 amplified breast cell lines and tumors, CREB3L1
mRNA expression was frequently increased, whereas in
TNBC cell lines and tumor samples, CREB3L1 expres-
sion was frequently low. As CREB3L1 has an important
role in metastasis suppression, its low expression in
TNBC may contribute to its more aggressive and meta-
static phenotype.
CREB3L1 is activated in response to cellular stress as
part of the endoplasmic reticulum stress response
process [53–55]. Viral infections and treatment with the
chemotherapy agent, doxorubicin, have also been shown
to induce cell stress and the activation of CREB3L1
[21, 24]. Tumors form in a stressful cellular environ-
ment with low nutrients and low oxygen levels (hypoxia),
suggesting that CREB3L1 may be activated during tumor
development and progression.
A recent study demonstrated that CREB3L1 expres-
sion was required for the chemotherapeutic agent doxo-
rubicin to block the proliferation of cancer cells [21].
Doxorubicin, but not other chemotherapy agents that
cause DNA damage (etoposide, bleomycin) or cell
cycle arrest (paclitaxel), cause increased ceramide
production that induces the trafficking of CREB3L1
from the endoplasmic reticulum to the Golgi complex
[21]. CREB3L1 has been shown to be proteolytically
activated and the mature protein translocated into
the nucleus where it could alter the transcription of
genes important for cell proliferation [21, 24]. As
doxorubicin was only effective in blocking cell prolif-
eration in CREB3L1-expressing cells, this suggests
that only patients expressing CREB3L1 are likely to
benefit from doxorubicin treatment. In support of
this idea, a recent report showed that higher levels
of CREB3L1 expression strongly inversely correlated
with tumor volume upon doxorubicin treatment in
renal cell carcinoma xenografts (r = −0.891; p = 0.017)
[22], leading to the suggestion that CREB3L1 could
be a biomarker that predicts doxorubicin treatment
outcome. These results also suggest that the loss of
CREB3L1 may contribute to doxorubicin treatment
resistance.
Fig. 8 Differential CREB3L1 mRNA expression between normal and tumor tissue for 48 human cancer types. Data obtained from The Cancer
Genome Atlas database, with the number of patients in each group indicated on the x-axis: median ± one quartile; *p <0.05; **p <0.01;
***p <0.001; ns not significant. Cancer tissues with CREB3L1 expression higher in tumor (T) than normal (N) (red asterisks) include: BRCA
breast carcinoma, PRAD prostate adenocarcinoma, KICH chromophobe renal cell carcinoma, CHOL cholangiocarcinoma, LIHC liver hepatocellular
carcinoma, STAD stomach adenocarcinoma, PAAD pancreatic ductal carcinoma. Cancer tissue with CREB3L1 expression lower in tumor than normal
(green asterisks) include: LUSC lung squamous cell carcinoma, KIRC clear cell kidney carcinoma, KIRP papillary kidney carcinoma, BLCA bladder urothelial
carcinoma, COAD colon adenocarcinoma1, PCPG pheochromocytoma and paraganglioma, READ rectal adenocarcinoma, SKCM cutaneous melanoma,
CESC cervical squamous cell carcinoma. Normal and tumor tissues with similar CREB3L1 expression include ESCA esophageal cancer, GBM glioblastoma
multiforme, HNSC head and neck squamous cell carcinoma, LUAD lung adenocarcinoma, SARC sarcoma, THCA papillary thyroid carcinoma, THYM
thymoma, UCEC uterine corpus endometrial carcinoma
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Other members of the UPR have been implicated in
tumor development. GRP78 has been shown to protect
tumor cells from cytotoxic T cell immune response and
apoptosis following Ca2+ depletion [56]. Additionally, in-
creased GRP78 expression has been associated with che-
moresistance in breast cancer [15]. PERK and XBP1 are
both important factors in tolerance of hypoxia; loss of
expression of either factor inhibits tumor growth and in-
creased apoptosis following hypoxia [57, 58]. Conversely,
decreased expression of UPR transducers has been ob-
served in the progression from normal to high-grade tu-
mors in mouse models of prostate cancer [53, 55]. It is
thought that increased activation of the UPR may impart
tolerance of hypoxia in some tumors, and downregula-
tion may promote tumor progression by preventing acti-
vation of apoptosis [55].
We have assessed human breast tumor samples of
various grades for the expression of CREB3L1. Low-grade
and medium-grade breast tumors had increased CREB3L1
expression, when compared to normal breast tissue sam-
ples. In contrast, high-grade (8 and 9) breast tumors had
reduced CREB3L1 expression (p = 0.001). Our results sug-
gest that CREB3L1 expression is initially upregulated in
response to the stressful conditions that exist within the
tumor environment, as observed for other stress response
proteins [53–55]. In contrast to other stress response
proteins, loss of CREB3L1 expression is prevalent in high-
grade tumors and may be required to avoid apoptosis
under prolonged stress conditions. This would allow the
de-repression of genes necessary for angiogenesis and
metastasis, which we have shown are negatively regulated
by CREB3L1 [25]. Overall, CREB3L1 was lost in 31 %
(67/213) of the human breast tumor samples analyzed, but
importantly CREB3L1 was lost from a much larger fraction
of the high-grade (8 and 9) metastatic breast tumors (51 %
of grade 8 and 73 % of grade 9 breast tumors; p = 0.001).
Thus, CREB3L1 may provide a cytoprotective effect early
in tumor development and later decreased expression
allows progression to high-grade tumors.
Our analysis also found that breast cancer patients
with low CREB3L1 expression have a shorter relapse-
free survival time specifically for the luminal A and
TNBC subtypes. As similar results were not seen for lu-
minal B and HER2 amplified breast cancers, the impact
of low CREB3L1 expression may not be significant in
the context of HER2 expression. This suggests that low
CREB3L1 is a marker for poor prognosis in both luminal
A breast cancer and TNBC.
Our data in human breast cancer cell lines suggest that
epigenetic silencing of CREB3L1 contributes to reducing
CREB3L1 mRNA expression for at least some cell lines, an
effect that was reversed by the inhibition of histone
acetylation with TSA and/or inhibition of DNA methylation
with DAC. We also found that some cell lines had little or
no CREB3L1 DNA methylation and yet, still had little or no
CREB3L1 mRNA. As methylation outside of the region
tested could also impact CREB3L1 transcription it is pos-
sible that other regions within the CREB3L1 gene also have
key roles in its regulation. In this regard the analysis of
TCGA data for CREB3L1 DNA methylation suggested
there might be additional CpG sites outside of the 688
nucleotides tested that could influence CREB3L1 mRNA
expression. For example, regions number 16, 19 and 20
(near the 3′ end of intron 1) all had increased methylation
in breast tumor samples as compared to normal breast
tissue (Additional file 9: Figure S5b), raising the possibility
that methylation in these regions could influence CREB3L1
mRNA expression.
In contrast, some cell lines had significant levels of
CREB3L1 DNA methylation, yet expressed relatively
high levels of CREB3L1 mRNA (e.g., MDA-MB-415,
MDA-MB-231). This could also be due to changes in
methylation within other regions of the CREB3L1 gene
that could impact transcription. In addition to DNA
methylation, CREB3L1 mRNA levels can also be influ-
enced by alterations in histone modifications, as well as
by the regulation of RNA processing, transport and sta-
bility [59, 60]. Further the high CREB3L1 mRNA levels
and low protein expression observed in some breast can-
cer cell lines (e.g., HCC202) could be the result of trans-
lational deregulation or the rapid turnover of CREB3L1
protein. An E3 ubiquitin ligase, HRD1, has been re-
ported to ubiquitinate CREB3L1 to induce proteasomal-
mediated degradation in C6 glioma cells and mouse em-
bryonic fibroblasts to maintain low levels of CREB3L1
protein [52]. Other cell lines have an abundance of
CREB3L1 protein, but very low levels of the correspond-
ing mRNA (e.g., HCC1500), raising the possibility that
the protein is not being turned over as rapidly in these
cells, perhaps as a result of defects in HRD1-mediated
ubiquitination and degradation.
Within the region tested (−429 to +259, numbering
relative to the translational start site), we noted that
for cell lines with less CREB3L1 DNA methylation,
the most frequently methylated CpG sites were 259
and 238. Cell lines with more methylation had an in-
creased number of methylated CpG sites 5′ to these,
suggesting that CREB3L1 DNA methylation proceeds
in a hierarchical fashion with some sites methylated
preferentially. Although the human breast tumor sam-
ples typically had lower levels of CREB3L1 DNA
methylation, they also had similar preferential methy-
lation at CpG sites 221, 238 and 259. The analysis of
CREB3L1 DNA methylation in breast tumors in the
TCGA database, also with suggested CpG sites 238
and 259 (i.e., region number 2), were usually more
methylated in tumors with low CREB3L1 mRNA ex-
pression (Additional file 11: Figure S7), but were generally
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less methylated in breast tumors than in normal breast tis-
sue (Additional file 9: Figure S5a). Together these results
suggest that CREB3L1 methylation at these sites in par-
ticular may negatively regulate CREB3L1 expression.
Overall, CREB3L1 expression was negatively correlated
with its gene methylation, suggesting that epigenetic si-
lencing is one mechanism that contributes to decreased
CREB3L1 levels. Increased CREB3L1 gene methylation
and low CREB3L1 mRNA expression were both corre-
lated with more aggressive types of breast cancer [61]
and higher tumor grade (8 and 9). We therefore con-
clude that the loss of CREB3L1 expression in cells of
high metastatic potential is due in some cases to methy-
lation of a region of CpG sites near the CREB3L1 start
site. In support of this, high levels of CREB3L1 DNA
methylation and low levels of CREB3L1 mRNA expres-
sion were more frequently observed in TNBC cell lines
and breast tumor samples. This is consistent with previ-
ous reports showing more DNA hypermethylation in
TNBC [62], in some cases due to overexpression of
DNA methyltransferase enzymes [63].
The subcellular localization of CREB3L1 also changes
with tumor progression. In low-grade breast tumors
CREB3L1 is predominantly a nuclear protein, consistent
with its processing into the mature form and translocation
into the nucleus as part of the cellular stress response to
activate CREB3L1. High-grade breast tumors that still
express CREB3L1 typically have mainly cytoplasmic pro-
tein localization, which likely would prevent CREB3L1-
mediated transcriptional repression of target genes that
promote cell growth, survival, migration, invasion, angio-
genesis and metastasis [25]. Similar subcellular localization
patterns of CREB3L1 are observed during bladder cancer
progression, suggesting a common function for CREB3L1
in at least these two cancer types [20].
Our results in TNBC and high-grade tumors are in
agreement with a recent study by Rose et al. who found
that CREB3L1 gene expression was downregulated in
bladder cancer and that the loss of expression was asso-
ciated with DNA methylation of the gene [20]. They also
reported that DNA methylation was associated with in-
vasive tumor subtypes of bladder cancer. In support of a
wider role for CREB3L1 in multiple cancer types, we de-
termined that CREB3L1 mRNA expression is altered in
many types of cancer (Fig. 8). Cancers of the breast,
prostate, kidney (papillary), stomach and pancreas all
had generally increased CREB3L1 expression in tumors
as compared to the corresponding normal tissue. Our
work in breast cancer suggests that this should provide a
protective effect. However, as we saw for breast cancers
with reduced CREB3L1, like TNBC, the disease is typically
more aggressive and advanced resulting in a poor prognosis
within these groups if tumors have reduced CREB3L1.
Importantly, we identified a large group of cancer types
where low CREB3L1 expression is prevalent, including lung
squamous cell carcinoma, melanoma and cancers of the
kidney (clear cell), bladder, colon, liver, adrenal gland,
rectum and cervix. This raises the possibility that loss of
CREB3L1 could play a key role in cancer progression and
metastasis across a broad group of cancer types.
Conclusions
In conclusion, we have demonstrated that CREB3L1 is fre-
quently upregulated in luminal and HER2 amplified breast
cancer, but not in TNBC. Tumors in TNBC are known to
have hypermethylated DNA and consistent with this, we
see enhanced methylation of several key CpG sites within
the CREB3L1 gene that strongly correlate with reduced
expression in breast cancer cell lines and in human breast
tumors. Low CREB3L1 expression is strongly associated
with more aggressive, high-grade tumors. Our results also
show that reduced CREB3L1 mRNA is an indicator of
poor prognosis, specifically in luminal A breast cancer
and TNBC. The discovery that CREB3L1 expression is fre-
quently altered in many cancer types suggests it could
have a broad role in cancer progression and metastasis. In
addition, loss of CREB3L1 expression could have prognos-
tic value for multiple forms of cancer.
Additional files
Additional file 1: Table S1. Primers for CREB3L1 gene sequencing to
determine methylation. (PDF 28 kb)
Additional file 2: Figure S1. CREB3L1 protein expression in a panel of
breast cancer cell lines. Cell lysates (50 μg protein/lane) from the
indicated breast cancer cell lines were probed for CREB3L1 and β-actin
(loading control). The full-length precursor form (approximately 84 kDa)
and processed mature form (56–58 kDa) of CREB3L1 are indicated (arrows).
A control lysate from HCC1806 cells transfected with HA-tagged CREB3L1
was also included (HA-CREB3L1). It has both the precursor (P) and cleaved,
mature (M) forms of CREB3L1, and as a result of the triple HA-tag, they are
slightly larger in size (approximately 6 kDa) than the endogenous CREB3L1
proteins. *Background band. (PDF 213 kb)
Additional file 3: Figure S2. CREB3L1 promoter region nucleotide
sequence with locations of CpG sites. Non-coding nucleotides (lower
case) and coding nucleotides (upper case) are shown. CpG sites are
highlighted (red and blue). The transcriptional start site (TSS) and the
translational start site (coding region) are indicated. The numbering is
relative to the translational start site (+1). The CpG island (−118 to +554),
as determined using the USCS genome browser, is located within the
boxed and shaded region. For the analysis of methylation in breast tumor
samples from the The Cancer Genome Atlas database the location of the
various cg probes are numbered, labeled and indicated with lines either
below or above the sequence. (PDF 48 kb)
Additional file 4: Figure S3. Analysis of CREB3L1 DNA methylation
for 40 breast cancer cell lines. a Schematic diagram of the CREB3L1
promoter region. The 5′ untranslated region (5′UTR; black box), the
coding region (gray box) and CpG island (hatched box) and the exon
and intron boundaries are indicated. b Sixty CpG sites were evaluated for
their methylation between −429 and +259, relative to the translational
start site. The frequency of methylation at each site is indicated.
Samples with less methylation, invariably had the more 3′ CpG sites
methylated preferentially (i.e., 259 and 238) and as more methylation
was observed additional CpG sites were methylated towards the 5′
end (as evident in Additional file 5: Table S2). c Examples of the
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scoring system used for methylation. Predominantly methylated sites
had a majority of C residues protected from sodium bisulfite conversion
and were assigned a value of 2. Somewhat methylated sites had
protected C nucleotides above background levels, but less than the
predominant T at the same site, and were assigned a value of 1.
Unmethylated CpG sites were scored as 0. (PDF 149 kb)
Additional file 5: Table S2. Site-specific methylation data for a panel of
40 breast cancer and 4 non-tumorigenic breast cell lines. (PDF 58 kb)
Additional file 6: Figure S4. CREB3L1 protein expression and
subcellular localization for each tumor subtype. CREB3L1 protein
expression and subcellular localization were determined for 97 human
tumor samples and 41 were found to have CREB3L1. a Luminal and
human epidermal growth factor receptor 2 (HER2) amplified breast
tumors had a similar proportion of tumors expressing and lacking
CREB3L1 protein. b HER2 amplified tumors had a higher proportion of
cytoplasmic CREB3L1 as compared to nuclear CREB3L1 when CREB3L1
protein was present. (PDF 40 kb)
Additional file 7: Table S3. Site-specific methylation data for the 35
breast tumor samples that contained methylated sites. (PDF 46 kb)
Additional file 8: Table S4. Probe information used in The Cancer
Genome Atlas (TCGA) database to analyze CREB3L1 gene methylation in
human breast tumor samples. (PDF 38 kb)
Additional file 9: Figure S5. Methylation in normal and tumor breast
tissue within specific CpG regions of the CREB3L1 gene. The Cancer
Genome Atlas (TCGA) database contained methylation data for 20
regions within the CREB3L1 gene (Fig. 6e) for normal and tumor breast
samples; the locations of these regions are indicated in Fig. 6f and
Additional file 8: Table S4. Some are also shown in more detail in
Additional file 3: Figure S2. a Methylation of CREB3L1 DNA in regions 2
and 3 are reduced in breast tumor samples, as compared to normal
breast tissue, and this negatively correlates with CREB3L1 mRNA
expression (c). Methylation was significantly different between tumor
and normal breast tissue in all regions except number 6: region 1
(p = 4.8 × 10−5), region 2 (p = 1.2 × 10−9), region 3 (p = 4.8 × 10−20),
region 4 (p = 0.0026), region 5 (p = 2.1 × 10−6), region 7 (p = 1.1 × 10−7),
region 8 (p = 7.6 × 10−6), region 9 (p = 1.5 × 10−18) and region 10
(p = 3.1 × 10−11). b Methylation was significantly different between tumor
and normal breast tissue in all regions except number 17: region 11
(p = 1.6 × 10−7), region 12 (p = 1.0 × 10−9), region 13 (p = 2.3 × 10−17),
region 14 (p= 0.00058), region 15 (p= 2.6 × 10−19), region 16 (p= 1.6 × 10−45),
region 18 (p = 9.7 × 10−9), region 19 (p = 1.8 × 10−45) and region 20
(p = 1.1 × 10−42). d In addition, methylation in regions 16, 19 and 20
increased substantially in breast tumor samples and positively correlated
with CREB3L1 mRNA expression. (PDF 294 kb)
Additional file 10: Figure S6. Methylation within specific CpG regions
of the CREB3L1 gene in different breast tumor subtypes. The relative
methylation was plotted for each tumor subtype. Methylation in regions
2 and 3 show an inverse correlation with CREB3L1 mRNA expression
(found in Fig. 6b), whereas methylation in regions 16, 19 and 20 show a
direct correlation with CREB3L1 mRNA expression. For all panels: normal
(n = 97), luminal (n = 357), human epidermal growth factor receptor 2
(HER2) amplified (n = 19), triple negative breast cancer (TNBC) (n = 113).
Statistical differences were analyzed using post-hoc pairwise comparison:
*p <0.05; **p <0.01; ***p <0.001. (PDF 97 kb)
Additional file 11: Figure S7. CREB3L1 mRNA expression varies in
breast tumors with CREB3L1 gene methylation in specific regions. For
each of the CpG regions shown, tumor samples were divided into low
and high methylation groups based on the level of methylation relative
to the median methylation in that region in normal breast tissue and
plotted according to the level of CREB3L1 mRNA expression for the
corresponding samples. Number of samples in each group: site 2: 418-L,
133-H; site 3: 451-L, 100-H; site 16: 114-L, 437-H; site 19: 32-L, 519-H; site
20: 27-L, 524-H. The median methylation in normal breast tissue was as
follows: site 2 (0.2556), site 3 (0.4189), site 16 (0.2708), site 19 (0.3352), and
site 20 (0.4669). Methylation was significantly different between tumor
and normal breast tissue in all regions: region 2 (p = 1.9 × 10−21), region 3
(p = 4.0 × 10−20), region 16 (p = 4.6 × 10−5), region 19 (p = 6.4 × 10−10) and
region 20 (p = 1.1 × 10−7). (PDF 39 kb)
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